dotinurad
Trade name: Urece
Small moleculeexperimental
Clinical trial activity
22 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
12
Phase 3
6
Phase 4
1
Earliest trial started Mar 1, 2013 (NCT02348307)
Timeline
Indications
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
SLC22A12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1cc(Cl)c(O)c(Cl)c1)N1CS(=O)(=O)c2ccccc21- Mol. weight
- 358.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594446 ↗
Also known as
- fyu-981
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07089888 | Phase 3 | Aug 4, 2025 | Crystalys Therapeutics |
| NCT07089875 | Phase 3 | Aug 1, 2025 | Crystalys Therapeutics |
| NCT06834230 | Phase 4 | Mar 3, 2025 | Saga University |
| NCT06056570 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Urica Therapeutics Inc. |
| NCT05278676 | Phase 1 | Jul 1, 2022 | Eisai |
| NCT05007392 | Phase 3 | Dec 31, 2021 | Eisai |
| NCT03372200 | Phase 3 | Jan 9, 2018 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT03375632 | Phase 1 | Jan 4, 2018 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT03350373 | Phase 1 | Nov 6, 2017 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT03350386 | Phase 1 | Nov 2, 2017 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT03306667 | Phase 1 | Oct 6, 2017 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT03100318 | Phase 3 | Apr 1, 2017 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT03006445 | Phase 3 | Dec 1, 2016 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT02901366 | Phase 2 | Sep 1, 2016 | Fuji Yakuhin Co., Ltd., Mochida Pharmaceutical Company, Ltd. |
| NCT02837198 | Phase 2 | Jul 1, 2016 | Fuji Yakuhin Co., Ltd. |
| NCT02515864 | Phase 2 | Aug 1, 2015 | Fuji Yakuhin Co., Ltd. |
| NCT02416167 | Phase 2 | May 1, 2015 | Fuji Yakuhin Co., Ltd. |
| NCT02347046 | Phase 1 | Jan 1, 2015 | Fuji Yakuhin Co., Ltd. |
| NCT02344875 | Phase 1 | May 1, 2014 | Fuji Yakuhin Co., Ltd. |
| NCT02344862 | Phase 2 | Jan 1, 2014 | Fuji Yakuhin Co., Ltd. |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fuji Yakuhin Co., Ltd. | For profit | 16 | 11 | 3 | 2013 |
| Mochida Pharmaceutical Company, Ltd. | For profit | 8 | 5 | 3 | 2016 |
| Crystalys Therapeutics | For profit | 2 | 2 | 1 | 2025 |
| Eisai | For profit | 2 | 2 | 2 | 2021 |
| Saga University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Urica Therapeutics Inc. | For profit | 1 | 1 | 1 | 2023 |
6 organizations
Page 1 / 1